Bristol-Myers Squibb Stock: Analyst Estimates & Ratings
Bristol-Myers Squibb has rallied the broader market over the past year, and analysts remain moderately bullish about the stock’s prospects.
BRISTOL MYERS SQUIBB (BMY) is drawing unusual attention today. Our newswire has captured 3 stories on BMY across 2 sources in the last 36 hours, with AI sentiment reading mixed (avg 57/100).
BMY stock is moving modestly higher in early trading, opening at $61.29 with a 0.9% gap up from the prior close. The upward movement follows news that Bristol Myers Squibb is expanding its AI infrastructure in partnership with NVIDIA. The company announced plans to build a powerful AI factory to accelerate drug discovery and development, which could enhance its research efficiency and competitive edge in the life sciences sector.
Bristol Myers Squibb is collaborating with NVIDIA to expand its compute infrastructure with the deployment of DGX SuperPOD systems. The new AI factory is expected to support proprietary models across the drug development pipeline, from target identification to clinical proof of concept. This move aims to reduce the time scientists spend on manual tasks, potentially speeding up the discovery of new therapies. The development comes amid broader industry speculation about potential M&A activity in the biopharma space, with investors identifying Bristol Myers as one of several possible bidders for promising assets.
The stock has traded in a narrow range so far, with a high of $61.29 and a low of $60.73 in the first five minutes of trading. Volume remains at 0.0M shares, which is 0.0x the 3-month average. Over the past eight sessions, BMY has declined 3.5%, falling from $58.03 to $55.98. The stock is currently trading within its 52-week range of $42.52 to $62.89. The company also announced a dividend of $0.63 per share, set to be ex-dividend and effective on July 2, 2026.
The stock is currently in a period of low trading activity. Investors may look for further developments in Bristol Myers' AI expansion and regulatory updates on its multiple myeloma treatment and mezigdomide NDA. Additionally, BMY is scheduled to release its next earnings report, which could provide further insight into its strategic direction and financial performance.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
Bristol-Myers Squibb has rallied the broader market over the past year, and analysts remain moderately bullish about the stock’s prospects.
Bristol Myers keeps making moves to establish a strong foundation for the future.
As investors rotate toward value, Altria, Bristol Myers Squibb, and American Electric Power stand out as reliable dividend stocks with strong payout growth histories and defensive appeal.
BRISTOL MYERS SQUIBB (BMY) is drawing unusual attention today. Our newswire has captured 3 stories on BMY across 2 sources in the last 36 hours, with AI sentiment reading mixed (avg 57/100). The most recent driver: "Bristol-Myers Squibb Stock: Analyst Estimates & Ratings" (Barchart).
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of BMY coverage reads 57/100 over 3 stories; treat it as a research signal and do your own diligence.
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More on BMY: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier BMY move explainers: 2026-07-20 · 2026-07-17